NASDAQ: $RARE A Breakthrough in Genetic Medicine The landscape for treating Sanfilippo syndrome type A (MPS IIIA) has officially changed. The FDA has granted approval for Fayuvi (rebisufligene etisparvovec-hopf), a pioneering gene therapy designed to address the underlying cause of this rare and devastating neurodegenerative condition. Understanding Sanfilippo Syndrome Type A Sanfilippo syndrome type A…